KR960704923A - HIV에 대한 면역응답을 유도할 수 있는 펩티드 및 그 펩티드를 함유하는 항 AIDS 예방·치료제(Peptides Capable of Inducing Immune Response to HIV and Anti-AIDS Agent for Preventing and Curing AIDS) - Google Patents

HIV에 대한 면역응답을 유도할 수 있는 펩티드 및 그 펩티드를 함유하는 항 AIDS 예방·치료제(Peptides Capable of Inducing Immune Response to HIV and Anti-AIDS Agent for Preventing and Curing AIDS)

Info

Publication number
KR960704923A
KR960704923A KR1019960701994A KR19960701994A KR960704923A KR 960704923 A KR960704923 A KR 960704923A KR 1019960701994 A KR1019960701994 A KR 1019960701994A KR 19960701994 A KR19960701994 A KR 19960701994A KR 960704923 A KR960704923 A KR 960704923A
Authority
KR
South Korea
Prior art keywords
peptide
amino acid
aids
acid sequence
hiv
Prior art date
Application number
KR1019960701994A
Other languages
English (en)
Other versions
KR100235849B1 (ko
Inventor
마사후미 다키구치
기요시 미와
Original Assignee
모치즈키 야스히로
아지노모토 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모치즈키 야스히로, 아지노모토 가부시키가이샤 filed Critical 모치즈키 야스히로
Publication of KR960704923A publication Critical patent/KR960704923A/ko
Application granted granted Critical
Publication of KR100235849B1 publication Critical patent/KR100235849B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

HIV의 전체 단백질의 단편으로서, 그 단편이 8~11개의 아미노산의 연속되는 서열을 함유하는 펩티드이고, HLA 결합 모티프에 상당하며, 실제로 HLA에 결합하고, 또한 HIV 감염세포를 표적으로 하는 킬리세포를 유도할 수 있는 펩티드를 개시한다. 이 펩티드는 항 AIDS 예방,치료제로서 유효하다.

Description

HIV에 대한 면역응답을 유도할 수 있는 펩티드 및 그 펩티드를 함유하는 항 AIDS 예방·치료제(Peptides Capable of Inducing Immune Response to HIV and Anti-AIDS Agent for Preventing and Curing AIDS)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 RMA-S-B*3501 세포상에 있어서의 HLA-B*3501 항원의 발현 레벨의 변화를 나타낸다. 도면중, △은 HLA-B*3501 항원 결합성이 있는 자기항원펩티드 28H(LPGPKFLQY), ○은 37F(LPFDFTPGY), □은 결합성이 없는 펩티드 MP-1(KGIGKVFTLTV)의 첨가에 의한 HLA-B*3501 발현 레벨의 변화를 나타낸다.
제2도는 펩티드로서 HIV(B35)-16을 이용할 때의 특이적 세포독활성을 나타낸다, 도면중, ●은 표지표적 세포가 T2-B*3501 세포일 경우, ○은 표지 표적 세표가 T2 세포일 경우인 콘트롤이다. 펩티드로 자극하여 배양한 환자말초 림프구는 1×105, 2.5×104또는 6.25×103개의 3단계 세포수를 이용하였으나, 도시된 특이적 세포독활성의 값은 1×105개의 세포를 이용했을 때의 것이다.

Claims (17)

  1. HIV의 전체 단백질의 단편으로서, 그 단편이 8~11개의 아미노산의 연속되는 서열을 함유하는 펩티드이고, HLA 결합 모티프에 상당하며, 실제로 HLA에 결합하고, 또한 HIV 감염세포를 표적으로 하는 킬리세포를 유도할 수 있는 펩티드.
  2. 제1항에 있어서, 그 펩티드가 9~11개의 아미노산의 연속되는 서열을 갖는 것을 특징으로 하는 펩티드.
  3. 제1항에 있어서, 그 펩티드가 서열번호 1~63중 어느 하나의 아미노산 서열을 갖는 펩티드인 것을 특징으로 하는 펩티드.
  4. 제1항에 있어서, HLA 결합 모티프가 8~11개의 아미노산 서열로서, 2번째가 Pro, C 말단이 Tyr, Leu, Ile, Met, Phe 및 Ala로 이루어지는 군에서 선택된 아미노산인 것을 특징으로 하는 펩티드.
  5. 제4항에 있어서, 그 펩티드가 서열번호 1~24중 어느 하나의 아미노산 서열을 갖는 펩티드인 것을 특징으로 하는 펩티드.
  6. 제4항에 있어서, 그 펩티드가 서열번호 1~13중 어느 하나의 아미노산 서열을 갖는 펩티드인 것을 특징으로 하는 펩티드.
  7. 제1항에 있어서, HLA 결합 모티프가 8~11개의 아미노산 서열로서, 2번째가 Pro, Ala 및 Gly로 이루어지는 군에서 선택된 아미노산이고, C말단이 Ile, Leu, Val, Phe 및 Met로 이루어지는 군에서 선택된 아미노산인 것을 특징으로 하는 펩티드.
  8. 제7항에 있어서, 그 펩티드가 서열번호 25~46중 어느 하나의 아미노산 서열을 갖는 펩티드인 것을 특징으로 하는 펩티드.
  9. 제1항에 있어서, HLA 결합 모티프가 8~11개의 아미노산 서열로서, 2번째가 Leu, Val, Tyr 및 Phe로 이루어지는 군에서 선택된 아미노산이고, C 말단이 Arg인 것을 특징으로 하는 펩티드.
  10. 제9항에 있어서, 그 펩티드가 서열번호 47~63중 어느 하나의 아미노산 서열을 갖는 펩티드인 것을 특징으로 하는 펩티드.
  11. 제1항의 펩티드를 코드하는 것을 특징으로 하는 DNA.
  12. 제1항의 펩티드 및 의약적으로 허용되는 담체 및/또는 희석제를 함유하는 것을 특징으로 하는 항 AIDS 예방·치료제.
  13. 제3항의 펩티드 및 의약적으로 허용되는 담체 및/또는 희석제를 함유하는 것을 특징으로 하는 항 AIDS 예방·치료제.
  14. 제4항의 펩티드 및 의약적으로 허용되는 담체 및/또는 희석제를 함유하는 것을 특징으로 하는 항 AIDS 예방·치료제.
  15. 제6항의 펩티드 및 의약적으로 허용되는 담체 및/또는 희석제를 함유하는 것을 특징으로 하는 항 AIDS 예방·치료제.
  16. 제1항의 펩티드를 AIDS환자에 투여함으로써 AIDS를 치료하는 방법.
  17. HIV의 전체 단백질의 단편으로서, 8~11개의 아미노산의 연속되는 서열을 함유하고, HLA 결합 모티브에 상당하는 펩티드를 합성하고, 합성 펩티드중 실제로 HLA에 결합하는 것을 선택하고, 이어서, 선택한 합성 펩티드중 HLA 클라스 Ⅰ 항원에 결합하여 HIV 질환환자의 말초 림프구를 자극하여 킬러세포를 유도하는 것을 채취하는 것을 특징으로 하는 HIV 감염세포를 표적으로 하는 킬러세포를 유도할 수 있는 펩티드를 채취하는 방법.
    ※ 참고사항: 최초출원 내용에 의하여 공개하는 것임.
KR1019960701994A 1993-10-19 1994-10-19 HIV에 대한 면역응답을 유도할 수 있는 펩티드 및 그 펩티드를 함유하는 항 AIDS 예방, 치료제(Peptides Capable of Inducing Immune Response to HIV and Anti-AIDS Agent for Preventing and Curing AIDS) KR100235849B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP93-261302 1993-10-19
JP26130293 1993-10-19
PCT/JP1994/001756 WO1995011255A1 (fr) 1993-10-19 1994-10-19 Peptide pouvant induire une reponse immune contre vih et agent contenant ce peptide pour la prevention ou le traitement du sida

Publications (2)

Publication Number Publication Date
KR960704923A true KR960704923A (ko) 1996-10-09
KR100235849B1 KR100235849B1 (ko) 1999-12-15

Family

ID=17359912

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960701994A KR100235849B1 (ko) 1993-10-19 1994-10-19 HIV에 대한 면역응답을 유도할 수 있는 펩티드 및 그 펩티드를 함유하는 항 AIDS 예방, 치료제(Peptides Capable of Inducing Immune Response to HIV and Anti-AIDS Agent for Preventing and Curing AIDS)

Country Status (8)

Country Link
US (1) US5756666A (ko)
EP (1) EP0728764A4 (ko)
JP (1) JP3814828B2 (ko)
KR (1) KR100235849B1 (ko)
CN (1) CN1055701C (ko)
AU (1) AU685521B2 (ko)
CA (1) CA2173138A1 (ko)
WO (1) WO1995011255A1 (ko)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US20020168374A1 (en) * 1992-08-07 2002-11-14 Ralph T. Kubo Hla binding peptides and their uses
ATE290592T1 (de) 1993-11-04 2005-03-15 Innogenetics Nv Von menschlichen t-zellen immunodominante epitopen des virus der c-hepatitis
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
BR9708161A (pt) * 1996-03-11 1999-07-27 Epimmune Inc Peptídeos com aumentada afinidade de ligação para moléculas hla
US6734287B1 (en) 1998-04-09 2004-05-11 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
EP0955311A3 (en) * 1998-04-09 2000-08-16 Idexx Laboratories, Inc. Peptide vaccine for canine allergy
US6667037B1 (en) * 1998-10-09 2003-12-23 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-B35 molecules, larger peptides which contain these, nucleic acid molecules encoding peptides, and uses thereof
WO2000023053A2 (en) 1998-10-20 2000-04-27 Salvatore Albani Artificial antigen-specific cells and related methods
US6787154B2 (en) * 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
US7807377B2 (en) 1998-10-20 2010-10-05 Salvatore Albani Method of isolating antigen-specific T cells employing artificial antigen presenting cells
NO311807B1 (no) * 1999-03-04 2002-01-28 Bionor Immuno As HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
CA2329152A1 (en) * 1999-03-30 2000-10-05 Idexx Laboratories, Inc. Peptide vaccine for canine allergy
AU757334B2 (en) * 1999-03-30 2003-02-13 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
WO2000073465A1 (fr) * 1999-05-28 2000-12-07 Ajinomoto Co.,Inc. Peptides capables d'induire des cellules tueuses specifiques du vih et agents prophylactiques/medicaments contre le vih contenant ces peptides
FR2794370B1 (fr) 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
CA2386499A1 (en) * 1999-10-05 2001-04-12 Epimmune, Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
EP1313505A4 (en) * 2000-09-01 2005-10-12 Epimmune Inc HLA BINDING PEPTIDES AND THEIR USES (18.03.02)
AU2003299134A1 (en) * 2002-05-20 2004-04-23 The General Hospital Corporation Cytotoxic t-cell epitopes of hiv-1 virus
WO2004024129A1 (en) * 2002-09-10 2004-03-25 Samir Chachoua Induced remission therapy
AU2003301012A1 (en) * 2002-12-13 2004-07-09 Case Western Reserve University Use of beta-defensins for treating hiv infections
US7442375B2 (en) * 2002-12-13 2008-10-28 Case Western Reserve University Compositions of beta-defensin inducing agents
US20060147997A1 (en) * 2004-11-30 2006-07-06 Virosys Pharmaceuticals, Inc. PenetraBodies: receptor-mediated targeted delivery of functionally-active human antibody fragments into cytosol for the treatment of chronic infections and diseases
UA97800C2 (uk) 2006-03-10 2012-03-26 Пептселл Лімітед Пептидні послідовності і композиції
JP2010516772A (ja) * 2007-01-26 2010-05-20 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド 免疫機能を調節する方法
CA2703585A1 (en) 2007-10-23 2009-04-30 The Regents Of The University Of Colorado Competitive inhibitors of invariant chain expression and/or ectopic clip binding
WO2010008554A2 (en) 2008-07-14 2010-01-21 The Regents Of The University Of Colorado Methods and products for treating proliferative diseases
US20100034839A1 (en) * 2008-07-25 2010-02-11 Martha Karen Newell Methods for treating viral disorders
US20100166782A1 (en) * 2008-07-25 2010-07-01 Martha Karen Newell Clip inhibitors and methods of modulating immune function
EP2323680A4 (en) * 2008-07-25 2013-05-01 Viral Genetics Inc PROTEINS FOR USE IN THE DIAGNOSIS AND TREATMENT OF INFECTIONS AND DISEASES
WO2011064779A2 (en) 2009-11-29 2011-06-03 Yeda Research And Development Co. Ltd. PEPTIDES DERIVED FROM HIV-1 gp41 TRANSMEMBRANE DOMAIN AND METHODS OF USE THEREOF
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
WO2014026033A1 (en) * 2012-08-08 2014-02-13 University Of Florida Research Foundation, Inc. Cross-reactive t cell epitopes of hiv, siv, and fiv for vaccines in humans and cats
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
JP2018528974A (ja) * 2015-09-25 2018-10-04 フロリダ大学 リサーチファウンデーション インコーポレイティッド ヒトおよびネコにおけるワクチンのためのｈｉｖ、ｓｉｖおよびｆｉｖの交差反応性ｔ細胞エピトープ

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS256960B1 (en) * 1985-11-16 1988-04-15 Viktor Krchnak Peptides with properties of antigenic determinants and method of their production
JP3011939B2 (ja) * 1987-03-02 2000-02-21 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 組換えミコバクテリア・ワクチン
US5128319A (en) * 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
EP0330359A3 (en) * 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Composition useful in the diagnosis and treating of hiv-1 infection
US4943628A (en) * 1988-06-13 1990-07-24 Ortho Pharmaceutical Corporation HIV peptide-inducted T cell stimulation
GB8918200D0 (en) * 1989-08-09 1989-09-20 Medical Res Council The peptide fragments of hiv
EP0510054A1 (en) * 1990-01-05 1992-10-28 United Biomedical, Inc. Hiv-1 core protein fragments
EP0968721A3 (en) * 1991-12-02 2004-02-04 The Board Of Regents, The University Of Texas System Use of a composition comprising a peptide for the inhibition of HIV
CA2157510A1 (en) * 1993-03-05 1994-09-15 Howard M. Grey Hla-a2.1 binding peptides and their uses
DE69430315T2 (de) * 1993-08-06 2002-11-21 Epimmune, Inc. Methoden zur (ex vivo) therapie mittels peptid - bestueckten antigen - praesentierenden zellen zur aktivierung von ctl

Also Published As

Publication number Publication date
EP0728764A4 (en) 1999-01-20
JP3814828B2 (ja) 2006-08-30
KR100235849B1 (ko) 1999-12-15
CA2173138A1 (en) 1995-04-27
CN1055701C (zh) 2000-08-23
CN1133597A (zh) 1996-10-16
EP0728764A1 (en) 1996-08-28
US5756666A (en) 1998-05-26
AU685521B2 (en) 1998-01-22
WO1995011255A1 (fr) 1995-04-27
AU7948794A (en) 1995-05-08

Similar Documents

Publication Publication Date Title
KR960704923A (ko) HIV에 대한 면역응답을 유도할 수 있는 펩티드 및 그 펩티드를 함유하는 항 AIDS 예방·치료제(Peptides Capable of Inducing Immune Response to HIV and Anti-AIDS Agent for Preventing and Curing AIDS)
Gustafson et al. Isolation, primary sequence determination, and disulfide bond structure of cyanovirin-N, an anti-HIV (human immunodeficiency virus) protein from the CyanobacteriumNostoc ellipsosporum
Moon et al. Glutamate dehydrogenase: amino-acid sequence of the bovine enzyme and comparison with that from chicken liver
DE69522216D1 (de) Zielzellen-bindende chimäre Peptide
EP0888122A4 (en) HYBRID FROM INTERFERON-alpha AND IMMUNGLOBULIN Fc FRAGMENT CONNECTED BY A MIGHTLY IMMUNOGENIC PEPTIDE
RU94045919A (ru) Антитела, клетки, полипептид, днк векторы, способ получения полипептида, способ получения антитела, фармацевтическая композиция
RU98120519A (ru) Аутоантиген и структурно-родственные ему белки для применения при иммунотерапии аутоиммунных заболеваний
KR850002283A (ko) 동종 면역 인터페론 단편의 제조방법
KR940703860A (ko) 신규한 사람 쿠니즈형 프로테아제 저해제 및 그의 변이체(a novel human kunitz-type protease inhibitor and variants thereof)
DE69310734D1 (de) Peptid für die stimulierung von für hepatitis c virus spesifischen cytotoischen t lymphozyten
Frey et al. Mechanism of target cell recognition by natural killer cells: characterization of a novel triggering molecule restricted to CD3-large granular lymphocytes.
RU98112759A (ru) Человеческий семафорин l (h-sema-l) и соответствующие семафорины в других видах
ABEL et al. Structural differences in the hinge region of human gamma A myeloma proteins of different subclasses
Chatterjee et al. Homology of adenoviral E3 glycoprotein with HLA-DR heavy chain.
KR920012440A (ko) 인간 인터류킨-5 수용체
GB9311454D0 (en) Pharmaceutical compositions
RU2001127439A (ru) Пептиды из последовательности Т-вируса и моноспецифические антитела, связывающиеся с ТТ-вирусом
IL75553A (en) Dna sequence coding for a cholinesterase-like peptide, peptides produced by cells containing said dna and antibodies thereto
AU4712993A (en) New peptides, antibodies raised against peptides and means for blocking said antibodies, application as medicaments, pharmaceutical compositions and utilization methods
KR20090009839A (ko) 면역조절 올리고펩티드
KR930703444A (ko) 어류 황체화 호르몬-방출 호르몬 동족체
Basava et al. Peptides: design, synthesis, and biological activity
GB1532169A (en) Fragments of secretin
NZ508812A (en) Peptides for the prevention or treatment of HIV
MX9206732A (es) Nuevas proteinas inhibidoras de trombina a partir de sanguijuelas de tierra.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20090925

Year of fee payment: 11

LAPS Lapse due to unpaid annual fee